Limits...
Beneficial effects of testosterone therapy on functional capacity, cardiovascular parameters, and quality of life in patients with congestive heart failure.

Mirdamadi A, Garakyaraghi M, Pourmoghaddas A, Bahmani A, Mahmoudi H, Gharipour M - Biomed Res Int (2014)

Bottom Line: Regarding changes in diastolic functional state and using Tei index, this parameter was significantly improved.Unlike the group received placebo, those who received testosterone had a significant increasing trend in 6-walk mean distance (6MWD) parameter within the study period (P = 0.019).The discrepancy in the trends of changes in 6MWD between study groups remained significant after adjusting baseline variables (mean square = 243.262, F index = 4.402, and P = 0.045).

View Article: PubMed Central - PubMed

Affiliation: Islamic Azad University, Najafabad Branch, Isfahan, Iran.

ABSTRACT

Background: According to the present evidences suggesting association between low testosterone level and prediction of reduced exercise capacity as well as poor clinical outcome in patients with heart failure, we sought to determine if testosterone therapy improves clinical and cardiovascular conditions as well as quality of life status in patients with stable chronic heart failure.

Methods: A total of 50 male patients who suffered from congestive heart failure were recruited in a double-blind, placebo-controlled trial and randomized to receive an intramuscular (gluteal) long-acting androgen injection (1 mL of testosterone enanthate 250 mg/mL) once every four weeks for 12 weeks or receive intramuscular injections of saline (1 mL of 0.9% wt/vol NaCl) with the same protocol.

Results: The changes in body weight, hemodynamic parameters, and left ventricular dimensional echocardiographic indices were all comparable between the two groups. Regarding changes in diastolic functional state and using Tei index, this parameter was significantly improved. Unlike the group received placebo, those who received testosterone had a significant increasing trend in 6-walk mean distance (6MWD) parameter within the study period (P = 0.019). The discrepancy in the trends of changes in 6MWD between study groups remained significant after adjusting baseline variables (mean square = 243.262, F index = 4.402, and P = 0.045).

Conclusion: Our study strengthens insights into the beneficial role of testosterone in improvement of functional capacity and quality of life in heart failure patients.

Show MeSH

Related in: MedlinePlus

Trend of the changes in 6-minute walk distance (6MWD) parameter (in meter) in intervention and placebo groups.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4109421&req=5

fig1: Trend of the changes in 6-minute walk distance (6MWD) parameter (in meter) in intervention and placebo groups.

Mentions: Comparing baseline variables and clinical parameters across the two groups who received testosterone or placebo (Table 1) did not show any significant difference, except for 6MWD that was higher in the testosterone group. During the 12-week study period, no significant differences were revealed in the trend of the changes in hemodynamic parameters including systolic and diastolic blood pressures as well as heart rate between the two groups (Table 2). Also, the changes in body weight were comparable between the groups, while, unlike the group received placebo, those who received testosterone had a significant increasing trend in 6MWD parameter within the study period (6MWD at baseline was 407.44 ± 100.23 m and after 12 weeks of followup reached 491.65 ± 112.88 m following testosterone therapy, P = 0.019). According to post hoc analysis, the mean 6-walk distance parameter was improved at three time points of 4 weeks, 8 weeks, and 12 weeks after intervention compared with baseline; however no differences were found in this parameter at three postintervention time points. The discrepancy in the trends of changes in 6MWD between study groups remained significant after adjusting baseline variables (mean square = 243.262, F-index = 4.402, and P = 0.045) (Table 3 and Figure 1). The muscle strength was gradually increased in intervention group but not in control; however, this trend was not different across the two groups (Table 2). Among cardiovascular parameters assessed by echocardiography, no differences were observed between the patients who were prescribed testosterone and those who received placebo from baseline to end of the study time (Table 4). Also, regarding changes in diastolic functional state and using Tei index, this parameter was significantly improved. However, quality of life score was significantly improved in former group after adjustment for confounders using the multivariate linear regression modeling (Table 5).


Beneficial effects of testosterone therapy on functional capacity, cardiovascular parameters, and quality of life in patients with congestive heart failure.

Mirdamadi A, Garakyaraghi M, Pourmoghaddas A, Bahmani A, Mahmoudi H, Gharipour M - Biomed Res Int (2014)

Trend of the changes in 6-minute walk distance (6MWD) parameter (in meter) in intervention and placebo groups.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4109421&req=5

fig1: Trend of the changes in 6-minute walk distance (6MWD) parameter (in meter) in intervention and placebo groups.
Mentions: Comparing baseline variables and clinical parameters across the two groups who received testosterone or placebo (Table 1) did not show any significant difference, except for 6MWD that was higher in the testosterone group. During the 12-week study period, no significant differences were revealed in the trend of the changes in hemodynamic parameters including systolic and diastolic blood pressures as well as heart rate between the two groups (Table 2). Also, the changes in body weight were comparable between the groups, while, unlike the group received placebo, those who received testosterone had a significant increasing trend in 6MWD parameter within the study period (6MWD at baseline was 407.44 ± 100.23 m and after 12 weeks of followup reached 491.65 ± 112.88 m following testosterone therapy, P = 0.019). According to post hoc analysis, the mean 6-walk distance parameter was improved at three time points of 4 weeks, 8 weeks, and 12 weeks after intervention compared with baseline; however no differences were found in this parameter at three postintervention time points. The discrepancy in the trends of changes in 6MWD between study groups remained significant after adjusting baseline variables (mean square = 243.262, F-index = 4.402, and P = 0.045) (Table 3 and Figure 1). The muscle strength was gradually increased in intervention group but not in control; however, this trend was not different across the two groups (Table 2). Among cardiovascular parameters assessed by echocardiography, no differences were observed between the patients who were prescribed testosterone and those who received placebo from baseline to end of the study time (Table 4). Also, regarding changes in diastolic functional state and using Tei index, this parameter was significantly improved. However, quality of life score was significantly improved in former group after adjustment for confounders using the multivariate linear regression modeling (Table 5).

Bottom Line: Regarding changes in diastolic functional state and using Tei index, this parameter was significantly improved.Unlike the group received placebo, those who received testosterone had a significant increasing trend in 6-walk mean distance (6MWD) parameter within the study period (P = 0.019).The discrepancy in the trends of changes in 6MWD between study groups remained significant after adjusting baseline variables (mean square = 243.262, F index = 4.402, and P = 0.045).

View Article: PubMed Central - PubMed

Affiliation: Islamic Azad University, Najafabad Branch, Isfahan, Iran.

ABSTRACT

Background: According to the present evidences suggesting association between low testosterone level and prediction of reduced exercise capacity as well as poor clinical outcome in patients with heart failure, we sought to determine if testosterone therapy improves clinical and cardiovascular conditions as well as quality of life status in patients with stable chronic heart failure.

Methods: A total of 50 male patients who suffered from congestive heart failure were recruited in a double-blind, placebo-controlled trial and randomized to receive an intramuscular (gluteal) long-acting androgen injection (1 mL of testosterone enanthate 250 mg/mL) once every four weeks for 12 weeks or receive intramuscular injections of saline (1 mL of 0.9% wt/vol NaCl) with the same protocol.

Results: The changes in body weight, hemodynamic parameters, and left ventricular dimensional echocardiographic indices were all comparable between the two groups. Regarding changes in diastolic functional state and using Tei index, this parameter was significantly improved. Unlike the group received placebo, those who received testosterone had a significant increasing trend in 6-walk mean distance (6MWD) parameter within the study period (P = 0.019). The discrepancy in the trends of changes in 6MWD between study groups remained significant after adjusting baseline variables (mean square = 243.262, F index = 4.402, and P = 0.045).

Conclusion: Our study strengthens insights into the beneficial role of testosterone in improvement of functional capacity and quality of life in heart failure patients.

Show MeSH
Related in: MedlinePlus